Valuation: Kinarus Therapeutics Holding AG

Market Cap 4.72M 5.68M 5.04M 4.28M 8.07M 547M 8.13M 56.65M 22.03M 279M 21.31M 20.85M 898M P/E 2022
-0.23x
P/E 2023 -0.01x
Enterprise Value 4.71M 5.67M 5.03M 4.27M 8.06M 546M 8.12M 56.54M 21.99M 279M 21.27M 20.81M 896M EV / Sales 2022
4,318,722x
EV / Sales 2023 -
Free-Float
-
Yield 2022 *
-
Yield 2023 -
1 day+8.39%
Current month+8.20%
Current year+8.20%
3 years 0.9
Extreme 0.895999
33.15
5 years 0.9
Extreme 0.895999
230.27
10 years 0.9
Extreme 0.895999
230.27

Financials

2022 2023
Net sales 3.34 4.02 3.56 3.02 5.71 387.12 5.75 40.07 15.58 197.48 15.07 14.75 634.86 -
Net income -34.73M -41.81M -37.11M -31.48M -59.45M -4.03B -59.88M -417M -162M -2.06B -157M -154M -6.61B -49.38M -59.44M -52.77M -44.76M -84.53M -5.73B -85.14M -593M -231M -2.92B -223M -218M -9.4B
Net Debt 1.66M 2M 1.77M 1.5M 2.84M 192M 2.86M 19.91M 7.75M 98.15M 7.49M 7.33M 316M -9K -10.83K -9.62K -8.16K -15.41K -1.04M -15.52K -108K -42.04K -533K -40.67K -39.79K -1.71M
Projected Income Statement - Annual - Kinarus Therapeutics Holding AG
Logo Kinarus Therapeutics Holding AG
Kinarus Therapeutics Holding AG is a Switzerland-based Company that operates as a biopharmaceutical industry engaged in diseases treatment. The Company conducts its work within clinical-stage area and its activities include discovery, examination and development of medicines that are intended for the treatment of viral, respiratory, and ophthalmic diseases. Kinraus therapeutic drug is patent protected KIN001 which is a combination of pamapimod and pioglitazone. KIN0001 offers oral, long-term treatment of diseases with severe impact on the comfort of living.
Employees
-
Sector
-
Date Price Change
07/10/26 CHF 17.45 +8.39%
05/10/26 CHF 16.10 -8.00%
02/10/26 CHF 17.50 -1.41%
01/10/26 CHF 17.75 -4.83%
30/09/26 CHF 18.65 +3.61%
  1. Stock Market
  2. Stocks
  3. CURE Stock